HUE033448T2 - Janus kináz inhibitor N-cianometilamidok - Google Patents

Janus kináz inhibitor N-cianometilamidok Download PDF

Info

Publication number
HUE033448T2
HUE033448T2 HUE14793899A HUE14793899A HUE033448T2 HU E033448 T2 HUE033448 T2 HU E033448T2 HU E14793899 A HUE14793899 A HU E14793899A HU E14793899 A HUE14793899 A HU E14793899A HU E033448 T2 HUE033448 T2 HU E033448T2
Authority
HU
Hungary
Prior art keywords
phenyl
amino
benzamide
pyrimidin
piperidin
Prior art date
Application number
HUE14793899A
Other languages
English (en)
Inventor
Ranjit C Desai
Jigar Desai
Pankaj Patel
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of HUE033448T2 publication Critical patent/HUE033448T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems

Claims (10)

  1. Janus kínáz inhibitor N - e i ano m e it 1 ami d o k Szabadalmi igénypontok 1. (I):
    A szerkezetű vegyüîet vagy gyógyászati lag elfogadható sója, ahol X valamennyi jelenléte eseten egymástól függetlenül X vagy CH közül, választott; X valamennyi jelenléte esetén egymástól függetlenül N vagy CE közül választott; n 0 és 1 közül választott, A egymástól függetlenül hidrogénatom, halogénatom, (1*4 szénatomos)- alki L OS, CN, CONtR.:};?, Ö(l~4 szénatomosj-alkilesöpört közül választott; a B gyűrű az alábbi:
    gyűrürendszerek közűi választóit, melyek mindegyike szubsztituált lehet.
  2. 2. Az i. igénypont szeműi vegy öletek. ahoi a B gyűrű szubsztituensei, amennyiben jelen vannak. egymástól függetlenül H, OH, CN, NHj, halogénatom, oxo, OOb, CF3, (1-6 szénato* mos)~aikil, 0(1*6 szé;natomos)-aikík (CH2)í*$ö(1*6 szénatomos}-a!kil, 0-(€l:b}o.,*0(1*6 szén* atomos)-«! ki 1, C(0)NH(1~6 szénatomos)-aikiI, NHC{())(1-6 szénatomos)-alkil, S(0)o.;(l-6 szénatomos)~alk ü, (CH2)^N(Rt)?, (CH2)^NHCí=0)0Rj, (CThh-cNI ICOOjR,, CíOlOR;, Ci—OjRi, NHR\, (CB^VAKCHjliMÁrj, {(.11;)0. N H{ C112k-4Ar5, ((.Ή,Ο^Λΐ''., (()lh)íi.4C(0)-{CH2)i>^Afh (C 1.(2)0-4(.-(=-0) 0(CH2)o-4Ari, (CH2)(mC(~Ü)NR *(CH2)^.4Ar * csö~ portok közül választottak. E Az 1. vagy 2. igénypont szerinti vegyület, ahol R* valamennyi jelenléte esetén egymástól függetlenül hidrogénatom, (1*4 szénátomos)~aikiL (1*4 szénatomos)-halogénalkii.
  3. (3-7 szénatomos j-cikloalkilcsopttfiok közül választott,
  4. 4. A 2, igénypont szerinti vegyület, ahol valamennyi Art jelentése egymástól függőtlenül szubsztituálatían vagy szubsztituált aril vagy egy, két, bárom vagy négy szidszfithenf| tártak mázó heterociklusos gyűrű közül választott.
  5. 5. A 4. igénypont szerinti vegyületek, ahol az Ar* csoporton álló szubsztíluensek egymástól függetlenül OH, CN, NH?, halogénatom, OCF;, CF3, (1 -6 szénatomos)-alkiK 0(1-6 szénatomos fal kik ((Hb)-.-60(1-6 szénatomos) -alkil, 0-(CHj)o-jÖ(l-6szénatomos)-alkíl, C(Ö)NHC( 1-6 szénatomos )-alk.ü, NHC(Ö)( 1 -6 szénatomos)~alki 1, S(0.)oo( > -6 szénatomos)-alkil, (CH3)?.6N(Ri)2, (CH2)uNHC(!!!0)0R|, (CH2)i-6NHC(=Q)Rt, CCO)ORS vagy -C(~0)Rj, CH2(CH2)o-4C{-0)NHRi csoportok közül választottak.
  6. 6. Az alábbiak közül választott 1. igénypont szerinti vegyület' N-(cianoinetí])"4-(2'({4«(4-(2*oxopirro!ídín'i»il)piperídin-l-il)fenn}araino)-píriínidin-4- ibbenzamid; N~(ciaiiometil)-4'-(2-((4~(4-'{l,l-dioxidoizotiaiïoIid?n“2“.il)piperklin*]~i])fenil)amîno)piriîuk.!in- 4-ij)benzamki; N-(cÍanomeUl)-4-'(2~((4-{4-morí'blinopiperidin''l-'iI)fenil)amjno)pírímidm-4-il}benz.anűcl;. 4-(2-í(4-(4-(lH-l,2>44nazobb-iI)pípOTdin-í-i:i)fenii)amino)pírímÍdin'4-ií)”N-(ciánométíl)benzamid ; 4-(2'<(4-i4~(lí:bpirazo}TÍ4l)píperidín44})íbmi)amino)pirímidin-4~il}”N~ (ciánomén bbenzam ki; 4-(2-((4-( [l,3?“bipînx>Hdin}-îMI}fenii)aTnino)pirimidin-4~U)“N*(cianümetH )-benzamid; N-(cÍanonieíi 1)-4-(2-((4-(4-( 1 (1 *diox|dotetmhidrO“2H>fciopiraní4>*il)piper«jzín-1 -iI)tenil)amino)pirimidin-4-i ! íben/amid; N-(eianometii )-4-(2-( (4-(4-(fim»i-2-íl)piperidin-l-il)feiiii)aniíno)pmraidia-4-il}benzamid; N-(cianometilj-4-(2-( (4-(4-( IJ-diöxidotetrahidrotíofen-S-ibpiperazin-l-ii }ícnil }amino}pirinndín~4~íI}benzamid; N-(eianom:etiI)-4-(2-((4~(4-(2,5-dioxopi.iTolidín-l-ü)piperidin-1 -il)fenil)« amino)piriniidin-4-íijbenzamid; \'-(cianomehb-4-(2-((444-{t?ofen-2-ü)piperidin-i«ibreni!}amino) pírimidín*4-ií)benzamid; N~(cíanometii}-4-(2-((4-{4-(2~oxooxazolídin-3-íl)piperidin-Í-ii)fenil)-amino)píriiTíidirí-4» ibbenzamid; N-(ciano.roetil )-4~(2-((4-(4~(tetrahidrofuran--2-1 bpiperkiin-1 -ií)feníi)amino j-pirim idin-4-il}benzamid; N-'(cíaftometib~4“(2~((4-(4-(5~meti!fiH'an-2-il)piperidin-I-il)feíiíi)amino.}pirimidin-4- ibbenzamid; N~(cianomelil)-4-(2-((4-(4-(íetrahidro~2Id-piran-4-il}piperazin'!-il)fefűba.núno)-pirimídin-4- ibbenzamid; N4cianometil)-4~(2-(í4-(4-(5-metiitetixdndK>iuran-2-ibpip®ridin-l-ibfeHÍl}amino)-pirímsdin- 4~il)benzan;iid' 4-(2-((4-(4-(6~oxa-3-axabkikíoj;3 J, .1 |hepUm-3-il)pipcridin- ! -iÍ)fen5!}í«nino)-pirimidin--4-í! .)-N-(ciánomét il)-benzamid; N-(eÍanometil)-4--(2-((4-(4“(2-oxoimidfKo!idin-l'-il)piperidi.n-l-il)feníí)amino)-piriniidin-4~ i{)benzamíd; 4-(2“((4--(4-(l>3í4-oxadiazoI-2-i!}piperídin-1-íl.)fenií)anúno) pirimidin-4-ib-N-(cimiometíl)benzamid* 4~(2-((4-(4~(2H~i;2,3--triazo]"24l)piperidir^l~íl}íeníI)aniino)pirimidin-4-il)-N“ (ciánoméi! nbeœamid; 4-(2-((4-(4-( i H-i J3~iriazoi~] - ü )p i per i d i n -1 - il)fcnillamiíio)pirimi cl i n-4 - i Π-N-(e iam> me~ tiijbenzamíd: N~ícianonietil)-4-(2-({4~(4-(5-oxo-]H-13z*4riazo!~4($H)-ii)piperidin~l-ií)teml)- aminü)pírimidín-4-.U)bcnzamid; N-(cianomot.il)-4-í2~((4-(4-{5-oxo-4f5-'díhidfo~l H~ 1,2,4-triazol-1 -il)ptperidin- 1 -Í1 )feni 1 }amino)pírimklm-4-il)benzanúd ; 4-(2-((4-(4-(1 -oxa-8~azaspiroj4,Sjdekan~8-il)píperidin”i-ií)feml}amino)pirimidi.n-4'i!)-N-> (cianomeíi 1 ibenzam id; N~(cianomcti ! )-4-(2-(( 4-(4-(5-metii-l 3?4-öxadifizoi~2-inp!poridm·'I -ilifenii)-ami no)pirirn i di n-4~i I ) benzamid; N-icianometil )-4-(2 -((4-(4-(5-metif~ 1,3.4-tiadiazol-2-il }pi peridin-1 -i Dlcníl }-araino)pirirnidín-4~:d)benzamid; N-(cia:noínetii)~4-(2-((4~(4-(íetrahidro-21i~(K4|dioxinoí2,3-c'Spirrobő(3il)-il}piperidín~l-i 1 ) feni ! ) am ino)pir im idin-4-i bbenzam id ; N-(eianometil)“4-(2-((4-(4-{2-oxo-l-oxa-8-azaspiro[4,5|dekan-8-ii)piperidin-l-ii)íeníi)aniino)pírimidm-4-il)beiizamid:; N-(cíanonmnil)-4~(2-((4-(4~(5-oxö-4>5“dihÍdro-l,3,4-oxadiazo]~2-il)piperidin-i- iÍ)feníl)amino)pi.rímidin-4-il)benzamid' K!'*(eianom.e{UM''(2,i!'((4-(4Hí4-eiklopi!opiÍ“5-metH'4H-l J,4-tnazoi-3-i!)piperidin-l-il)fenií)Mríno)pirimidín-4-íi)benzamid; ΝΚεΐ8πο.ηΐϋΐι1)'4»(2-((4·'(4·-(5~ιη«{οχί-^3'4“θχ»(ΪΪ82(θ!*24ί)ρ.ίρβίκ1ΐη-Ϊ>ΐφ·δ;ηΗ)''· a m ino)pi rím idm -4-d }benzarn í d ; 4-(2-((4-(4-( L4-dioxi(pan-6-il}piperaziiirl-iI)iemi)am:ino)pirinndin~4-.i!)-N-(ciarionietil) henzamid; N«(cíanometil>4-(2>*((4-(4-(4,$*clthidrO“lH4midaKOl-2~U)piperazin*'.l «U )feail> ami no)pi ri m i di n-4-ί I ) beaza mid ; N -( c tanom éti I)-4~f 2~({ 4-(4 ~(4?5-0ί hí dro~ 1Ϊ î-i m idaÄol-2-ΊΙ >pi peri cl í íi -1 -i l)fen íl )-ami no)pirimi din-4-il)henzanmi; N-(ciaHomt4i{)-4-(2-((4-(3-(tetîaliidro-2îl-f L4|dioxi.maf'2J-cjpirrol-6{3i:í)-íi)pirrolidin-l·-í Illeni barnino Jpírim idi n-4-ü)benza.nríd : N-(eíaftometil)~4-í2~((4~(4~í 5-meti 1 -1 >3,4-oxad iazol-2-i bpiperazin- Î -ii)íenil> amí nojpirirö ídiÉ*4»Í í )feenzamid; N-{cia)K?metií}~4-(2~((4-(4^3,4-dil'adro>;ipírroíkHn~l-ií)pipüríd.in~l~i])íeníl)araino}-p5rÍ!Tíidin~ 441)benzamkl; 4-(2~({4-(4'-{8"í>Ka~3'-azabiciklo[3.2.I }ocian~3~íÍ)píperidín~l -il)fení})amino)- pirímkün-4-ii}-N~(cianometi!)benzamid; 4424(4«(4-(ő-aceíik3,6«diazahiciklo(34 J]heρtan-341)pipefidin-14!)fenil)~amino)pirím^din-44 i)- N -í c i anom et i l)benzam id ; N-(cianoraetíÍ)«4^{5*metíb2-((4-(4rraoríbiínopiperidin--14í)fenil)aniiiio)pífimidin-4'· ii)benzami<l; N-(eianometi í)~4-(5-meti í-2-((4 - ( 4-(2 ~ o xo p i rro i í di n ~ 14 í)piperkün-l 41) feni i pamínojpirúníditn 441)benzamid; 442^((4^(4~(l^oxa-8”azaspiro[4.5idekan-'S~íl}piperidin-]~íi.)feml)aniino)~5-'meti!pirimidín-4- iÍ)^N-(cianomeUi)benzamid;. N»(cianometil)-4*‘(5«.rnetib24(4*{4’'(5«inaetik L3,4OxadiazoÍ-2“U}piperidin-Í -fl}fenii)aínhK>)pirimidíív-4-íl)benz.a,wíd; N-(cíanomt4iI}4-(5-iíiior-2>'((4'44'mofik4inopiperidin-l4i)fenil)aniíno)pífímidin->4- iljbenxannd; 4-(5-kÍór-2-{(4-(4~morrolínopiperidín~i”il)fenil)aiívino)pírií«ídin'-44Í}~N- icianoineblfbenzamid:; N-(eianometii}>4-(5~fluor*2'{(4"(4-{2-oxopinOtidin>l“U)piperidin"i"il)fenii)-amino}pirjmidin“ 44l)benzamid; 4-(54dór«2-((4*(4~(2“OxopKToUdin> I 4 i)piperidin~ ! 4l)feni! }auTtino)pí rimîdin-4-nj>N,> (ci anom etíl)benzamid; 4-(24(4~(4~(6~oxa-3-azabktklo(3. í. \ ]heptan>3~U)ptperidifl-l 41)foni1)ammo>5* metiÍpÍnmidin-44!)~N-{eianometü)benzamid; 4~(2-((4-(4-(6-oxa»3«azabicik}o(3.i. 1 ]hepian-3-il }piperidi«-I 4 ! }tbmI}atn!no)-5~fluofpifimidir5-4 - i 1 )-N- (ciánoméit l)benzamid ; 442*((4-(4-(6-oxa-3~azabicíkioj'3,l.i ]hep?an-34Í)píperidin44i)fenii)amirio)-54dórpirímídm-44 !)-N-( c í anom éti 1 )benzan í íd ; N-(cíanometil)-4-(5-meti!-2-({4“(4-(íetrahidro-2H-(L4]dioxino[253-c]pirroi"6(3H)·' ii)piperidin-141}fenii}andno)pirimidin-4”il)benzainid; N'{cia3iCHnetii)-4"(5“iluor~2~((4444tetrahsdro-'2I-b}’ 14]díoxíno|2.3*c]pirrol-6(3HV i))piperidm~i41}fenil)amino}pinmidin-441)benzamid; 4”($-klór-2-((4-(4-(tetrahídro-2í L4 i .4jdio.Kinof2,3~e]piffol-6(3I-l)41)pipendin-l -íÍ)ílnnl)amino}pirhnidm"441}'N-4cia3K>meüÍ)benzamid; N-(cíanoraetil)-4-(5-i1uor~2'-((4»(4-(5^oHít.ii-I3i4"DxadiazoI-2~íl)píptóridin-l- ii)fenil)aíTÚívo)pirivn\dín-4~U}benzamíd'. 4«(5-klór-2-((4-(4-( 5«metil-l,3,4~oxadjazol-2-iÍ)piperidin”i-ü)feml)am.uK>}-pirimidin~441)~N-(c i anom éti ! )be nzam i d ; N-(C:ianoTriet.il)~4-(5~metiK2~({4-(4-(5-'iíietibl3i4r05iadía/.ob2dí)pípcraíí;ÍB^Í^ i ijfenil )am.ino}pírimidi n-4-i 1 )benzam id: N~(cianomeii!}-4"(5-fluoi'“24(4-{4-(5-iTietii-'K3,4~oxadiazoi~2-äl}piperazin-l- íl}fertií}öSTÚTK3)piriniídm~4~íl}benzamid: 4-(5-kiór*24(4<445-metÍl-l,?K4HXxadiazoi-2~ii)pipera/Jn-4 41)feíil)amino)~p:irímidin-4--ii)-N-(ciánomét! Dbenzamid : 4-(2-((4-(4-(3-tia-6~azabicík]o[3> 1.1 Jheptan*64l)piperidm» 1 -ii)fenil}amíno}~pírim?din-4~H}-N-' (ciánomét! i)beirz.amid: 4-{2~((444~(3“tiö'4>-azabiciklo[34 J|hepían-6-ii)piperidin-l”ii)feni!}amjno)~5-'ír!eíÍlpiriniidíi}-44ί)4Ν-(οί3ηοπΊ^ΗΐΙ}Β6ηζ3ΐηίί1; 4-(2-í (4-(4-( 3“da-6-azabíciklö[3.l d]hcptaiv-64i}piperidía-l4í).femi.)annno)-5-i']uorpíríaddi% 4ril)~N-(cianomedi)benzamid; 4-(2-((4~(4-(3~tia-6~azabieik}o[3,L1 jhepta«-6~íi)piperidín-l-il)fenil)amÍ3io)-5-kk>rpiriirddia^ 4-i 1) -N-{e ianometi i)benzaro i d.
  7. 7. Az előző igénypontok bármelyike szerinti vegy öletek közül választott alábbi vegyületek: N-(cianometil)-4-(2~{(4-{4~(2~oxopin'olidin-l-il)piperidiTi-1~ii)fenii)amino)"piriniidir!-4- il)benzamíd; N!-('eianometii)-4-(2-((4-(4-(lJ'dioxidoi/otíazi.'lidin-2-ü}piperidin~l -ti)- fenil)ammo) p í r im í d i n-4 ~H ) be nzamid ; N-(c)anometil)~4-{2-{{4-(4-mot1blinopiperidin~ I-íDlenil )am ino)pmmidin-4-il)benzamíd; 4-(2-((4-(4-(lΗ-1.,2,4-triazol-l -il ipiperidin-i ~il)íéni 1 }amino) pírimidin-4-ií)~N-(ciariometíí)benzamid; 4-(2-(4-((4-( l H-pirazo.!~l -.11 }pl peri din-1 ~i 1> feni l)amino)pirimidin-4-il )-N-(cianometil)benzamid; 4-(2-((4-([‘î!r3,-bîpîrroîidin|-lî-U)fenii)iU'nmo)pirimidm~4-ii)~'N-(cianometii)- benzamid; N-(eianometil)-4-(2-({4~(4-í I, ! -dioxídotetrahtdro-2H -1iopíran-4-í 1 )piperuzin-1 -i 1} ten i 1 tat π i no )ptri mi di n-4-i l)benzam id ; N~(eíanometil)~4-(2-((4-í 4-t íuran-2-il }piperidin4~il Jiénil )amino)ptrtmitlitt-4-il }benzamid; N-(cianoroeiil )-4-(2-( {4-(4-(1,1 -dioxidotetmhidtx>{iofeß-3ril)ptperazin~ 1 -i lifers i l)ami no ) pi ri m tdín-4-i 1) benzamid ; NH'd8nome{jl)-4~(2-((4-(4-(2i3-dioxöpirroIidin-]-ii)piperidin-i-il)ieniI)amino}~pirimidin-4- il)benzarnid; N-(cianotneíiÍ)-4-(2"((4'(4-(tiofeíJ-2-n)piperidin-l*il)fcni!)amino) pi ri m id i n-4 -11 ) benzam id : N-(cíano-m6til)“4-(2“((4-(4-(2-o.'cooxazolidin-3-il)piperidin-l”ií)feníI) amino )- pirimi di n-4-lllbenzamid; N“(cíanom<ííi!)-4“(2'((4-{4-(ic{röhidrojíuran-2-il)píperídm-i-iÍ)ieníl.)amÍno}”pinmidin“4- il)benzarn.id; N~(ciaxKmmtí].)-4~(2-{(4-(4~(5-meníiuran-2-ii)pipcrídin-1-il)íe«il)amíno)pírímídin~4~ 31)benzm«id; N'-(cianometíl)-4-(2-((4-(4-(tetrabidro-2íi-píran-4-il)pipcrazin~l*il)ft*nil)amino)-pirhnidin-4- iljbenzamid; N-(cianometii}“4-(2'((4-(4-{5-metíitetrahidroíUran-2-ii)pipendin-l-il)rerHÍ)-amino)pirimidin- 4-il)benzamid; 4-(2 ~((4-{4~(6-oxa-3-azabiciklo[ 3.1.1 jheptaTK3-iI)piperidin-14I)fenil)amino)-pirimidin-4-il)-N ~( cb.mom etil )benzam id ; N-(eianometd)-4-(2-((4-(4~(2-oxoimida2olidin-'l”il}pipeHdiiel -ii)}eTvil)amino)-pirtmidin-4-il)benzamid; 4-(2-((4-(4-( 1 * 3,4-ox adi azol -241 )p i per i d ί η - i. -U)fenil)amino) pirimi din-4-ii)-N~ (cianomeiil)benzamid; 4-(2-((4-( 4~(2H-L2.3-triazol-2-il)piperidm-1 ~il)feni! )am ino )pi rim id in-4 - i !)-N ~ t eianometiijhenzamid; 4-(2-((4-(4-( lJ:l~i;2,3-triaKol-i-iI)pipiaidin-i-ri)forir)amiru.^irimidm-4-iJ)-N-(cianomeii 1 ihenxamid ; N-(ciaxxoinetti)-4~(2-((4~(445-oxo-lII-L2,44riazol-4(Sid)-il)piperidire1-il.)fenil) amino) pírímidin-4-ií)benzamid; N-(eianonietil)-4-(2-((4~(4-(5-oxu~4f 5-díhidro-1 H-1,2,4 -tri azo 1-1- i 1 )pi peridin-1 -i I ) fen í I )ami no )pi ri mid i n -4-i l)hers zam i d ; 4-(2-((4-(4-( I -oxa-8-azaspíro[4,5]dekan-8-il)piperidin-1 -il)fenil)anitno)~pirimidin-4-ii )-N-( c : arsons eti 1 }benzam id: N-( ciánom etil )-4-(2 -( ( 4-( 4-(5-meti I- Î ,3s4-oxadiazoI-2-H)pÍperidin-Í-H)fenil}-a m i no )phimi di n-4 ~i 1 ) be nza m I d ; N-(cianomeül)«4-(2>((4-(4-(5-metií~] ,34Μΐ3ΐ.ϋαζοΪ”2-ϋ}ρ{ροπ<ϋη·Ί”ϋ)Γοηί1}··αΐΏίηο)ρΙι·ΐπΰίϋη-4~íl)benzaraid; N-(cianometi l)-4-(2-((4-(4-(tetïahidro-2H-[ 1 ^|dioxmoí2,3~c]pirroí~6{3H)~}l)piperidin-> 1 -i í )íenü)am inö)pirímid m-4~íi)benzam i d ; N4ciano.metíl)-4a24(444~(2H)xo-í-oxa--8~azaspiro[4.5]dekaH"8"il}piperídín-i-íijfeni i )am ino)pif imMin-4»il)benzamid ; ·ΝΚα3ΐι.οιηβΐί1>4-(2-((4^(4~(5·'θχο«·4<5*^Ι^ΐώΌ“ί,3»4*οχ8^Ϊ32οΙ*24Ι)ρίρβτΐά*η«·Ϊ·“· i 1 ) fen i I )am i no )pi inni di n-4-i í }benzam í d ; 'N-(cianofneUI)-4-(2-((4-<'4-(4'CiWopropii~5-metn"'4H-K2,4-iriaïrol-?)-il)piperidin-l- ií}tenií)aHvmo)pirimkiíí\-4^i]}beu£amid; N-(cianomctU)-4”f 2«((4*(4-(5-metoxj» 1^4-oxadiazo!~2~ü)píperidm-1 -? l)fenü>· ammo)pinnúdln~4-il)benzamki; 4-{ 2-((4-(4-( l(4-dioxepan-6-il)pipera?in-J-i})feni])amino}pirimidin-4-il)-N-(cianometii) benzarnid; Ν'-í cianomeül )-4-(2-((4-(4-(4,5 ~d i h kirn -1 H-imidazol-2-il )piperazin-1 ~í) )feni !)-ara i no )pí rimidin-4 -II ) henzam íd ; N''(ciauoraetil)-4-(2-((4-(4-(4,5'dihklrO'lH4midazo!-2-!l)pipcridin-l-ii)fenil)- ainino)pirimidin-4-i!)benzaTrfid: N-(cíanomeíi!)-4~(2-((4-(3~((aírahidro-2H-[l,4)dioxino[2,3-c|pínOl~6(3H)~Il)pirfo!idin-l" d)fenii)airnjK>)pirimídiív-4~i])henzamid; N'(cianoractii)-4-(2"((4-(4-(5-nraíi!~L3,4-oxadiírao!-2-il')píperaziivi'-il)fenií)“ amino)piríraidín-4-!Í)benzaraid; N~(cianomedl)”4~(2-((4-(4-(354-dibidroxipirroiidin~i~ü)pipefidin-l-'ii)fen.ü'hamiiK})pirimidira 4~i])benzamid; 4-{2-'((4-(4-(8"Oxa~3-a^abiciklo[ 3,2. l]ocían-341 jpiperlüi«- 1-il )íenil)amino) -pirimidin~4“ií)-N-(danoraeíi!)benzaraid; 4-(2-((4-f4-(6~Aceti!-34kdiazabicikio|34djhepían~2)-ií)piperidin~l~íl)íenii}-amino)pk>iínidin- 4-íl)-N'(cíanonietií)benza!rad( N~(c:íai»3iíraül)-4-(5-mcníl-2-((4-(4-raorfolínopiperídifs-l-'il)fenii)araii'io)piríittídin-4- ii)benzanbd; N-(cjarto«ieti!)'44S-«jetil-2-((4-(4-(2-oxopi.rro}.idin-i-iU)pipendin«14} )í2röil}-ann.no)pjriraidin-4-il)benzainid; 4-|2~((4"(4*|l><-nxa-S-azaspiro|4.5]dekaii-84i)píperidm' i -il)feiií)amjno)'-5~metilpínraidinr4·* i í)-N-(cianomet.í l)benzaraid: N»(cianometi!)-4-(5~metil-2H(4-{4"(5-metii-í ^^-oxadiaz.oi^-iOpiperidin-l-iiJfenilJaminoJpirimidin-d-il)^^ N“(cÍaímmetíl)-4-(5-nuor-2-((4-{4~morfotínopi peridin-l-ii)téníl)ammo )pirimidin-4-il)benzanűd; 4-{S”klór«2~í(4-(4~rnorfolinöpiperídín~14l)fenií)amíno)pirimidin-4~Íl)-N- (eianometil)benzamid,
  8. 8. Gyógyászati készítmény, mely terápiásán hatékony mennyiségű előző igénypontok bármelyike szerinti vegyüietef és adott esetben egy vagy több gyógyászati lag elfogadható hordozóanyagot., hígílőszert vagy kötőanyagot- tártálm az.
  9. 9. Az előző igénypontok bármelyike szerinti vegyidet gyulladásos állapotok, autoimmun betegségek, proliferativ betegségek, allergia és transzplantálum kilökődés, porc mozgás romlásával, veleszületett porcelváhozásokkal összefüggő betegségek és/vagy 1L6 vagy interferonok túltermelésével - aboi a JAK kínáznak patoílziológiás funkciója van - összefüggő betegségek kezelésében történő alkalmazásra.
  10. 10. Gyulladásos állapotok, autoimmun betegségek, proliferativ betegségek, allergia és transzplantálum kilökődés, porc mozgás romlásával, veleszületett porcelváhozásokkal összefüggő betegségek és/vagy 11,6 vagy interferonok túltermelésévei összefüggő betegségek kezelésére alkalmas gyógyászati készítmény, mely az l. igénypont szerinti vegyületeket megfelelő kötőanyagokkal együtt tartalmazza. Π. 4;
    képlető intermedier, ahoi B, Z, X, n és A az 1, igénypontban megadott.
HUE14793899A 2013-08-07 2014-08-06 Janus kináz inhibitor N-cianometilamidok HUE033448T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2611MU2013 IN2013MU02611A (hu) 2013-08-07 2014-08-06

Publications (1)

Publication Number Publication Date
HUE033448T2 true HUE033448T2 (hu) 2017-11-28

Family

ID=54199342

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE14793899A HUE033448T2 (hu) 2013-08-07 2014-08-06 Janus kináz inhibitor N-cianometilamidok

Country Status (16)

Country Link
US (1) US9556148B2 (hu)
EP (1) EP3030561B1 (hu)
JP (1) JP2016525071A (hu)
KR (1) KR101665301B1 (hu)
CN (1) CN105612154A (hu)
AR (1) AR097282A1 (hu)
DK (1) DK3030561T3 (hu)
ES (1) ES2618072T3 (hu)
HK (1) HK1222386A1 (hu)
HR (1) HRP20170277T1 (hu)
HU (1) HUE033448T2 (hu)
IN (1) IN2013MU02611A (hu)
PL (1) PL3030561T3 (hu)
PT (1) PT3030561T (hu)
TW (1) TWI562990B (hu)
WO (1) WO2015019365A1 (hu)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105801910A (zh) * 2016-06-01 2016-07-27 扬州兰都塑料科技有限公司 一种电力电缆阻燃助剂
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1286302B1 (it) 1996-04-10 1998-07-08 Rotta Research Lab Chinazoline-4-amino-2-(piperidino-1-il-4-sostituite) ad attivita' anti-ipertensiva, procedimento per la loro preparazione e loro uso
AU777594B2 (en) 1999-05-24 2004-10-21 Mitsubishi Pharma Corporation Phenoxypropylamine compounds
GB0012240D0 (en) 2000-05-19 2000-07-12 Merck Sharp & Dohme Therapeutic agents
EA006205B1 (ru) 2000-11-02 2005-10-27 Уайт 1-арил- или 1-алкилсульфонилгетероциклилбензазолы в качестве лигандов 5-гидрокситриптамина-6
TW200407127A (en) 2002-08-21 2004-05-16 Astrazeneca Ab Chemical compounds
DE10250708A1 (de) 2002-10-31 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
ITMI20040954A1 (it) 2004-05-12 2004-08-12 Univ Degli Studi Milano Derivati del 3,6-diazabiciclo 3.1.i.eptano ad attivita' analgesica
ES2427046T3 (es) 2004-06-21 2013-10-28 Galapagos N.V. Métodos y medios para el tratamiento de la osteoartritis
JP4624315B2 (ja) 2005-12-20 2011-02-02 株式会社リヒトラブ 綴じ具
BRPI0706747A2 (pt) * 2006-01-30 2011-04-05 Exelixis Inc 4-aril-2-amino-pirimidinas ou 4-aril-2-aminoalquil-pirimidinas como moduladores jak-2 e composições farmacêuticas que os contenham
US8754107B2 (en) 2006-11-17 2014-06-17 Abbvie Inc. Aminopyrrolidines as chemokine receptor antagonists
KR101737753B1 (ko) * 2007-03-12 2017-05-18 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 페닐 아미노 피리미딘 화합물 및 이의 용도
TWI433677B (zh) 2007-06-04 2014-04-11 Avila Therapeutics Inc 雜環化合物及其用途
WO2009029998A1 (en) * 2007-09-06 2009-03-12 Cytopia Research Pty Ltd Retrometabolic compounds
EP2205572B1 (en) 2007-09-19 2011-07-13 Albemarle Corporation Methods for production of 1,2,4-triazol-3-one
TWI475996B (zh) 2007-10-19 2015-03-11 Celgene Avilomics Res Inc 雜芳基化合物及其用途
US7989465B2 (en) 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
CN102007124B (zh) * 2008-02-15 2014-06-18 里格尔制药公司 嘧啶-2-胺化合物及其作为jak激酶抑制剂的用途
KR20170051521A (ko) 2008-04-16 2017-05-11 포톨라 파마슈티컬스, 인코포레이티드 ｓｙｋ 또는 ＪＡＫ 키나제 억제제로서의 ２,６－디아미노-피리미딘－５－일－카르복스아미드
KR101623997B1 (ko) 2008-04-16 2016-05-24 포톨라 파마슈티컬스, 인코포레이티드 ｓｙｋ 또는 ＪＡＫ 키나제 억제제로서의 ２,６－디아미노－피리미딘－５－일－카르복스아미드
ES2711249T3 (es) 2008-06-27 2019-04-30 Celgene Car Llc Compuestos de heteroarilo y usos de los mismos
WO2010039518A2 (en) 2008-09-23 2010-04-08 Rigel Pharmaceuticals, Inc. Tricyclic carbamate jak inhibitors
US8268851B2 (en) 2008-12-23 2012-09-18 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
JP5815411B2 (ja) 2008-12-30 2015-11-17 ライジェル ファーマシューティカルズ， インコーポレイテッド ピリミジンジアミンキナーゼ阻害剤
DK2389372T3 (en) 2009-01-23 2015-12-14 Rigel Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR INHIBITION OF JAK pathway
WO2010129802A1 (en) 2009-05-06 2010-11-11 Portola Pharmaceuticals, Inc. Inhibitors of jak
WO2010139717A1 (de) 2009-06-05 2010-12-09 Boehringer Ingelheim International Gmbh Neue verbindungen
EP2459195A1 (en) 2009-07-28 2012-06-06 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
DE102010003599A1 (de) 2010-04-01 2011-10-06 Lisa Dräxlmaier GmbH Verfahren zur Kabelkonfektionierung sowie konfektioniertes Kabel
WO2013010453A1 (en) 2011-07-15 2013-01-24 Abbott Laboratories Chemoking receptor antagonists
WO2013093940A1 (en) 2011-12-20 2013-06-27 Council Of Scientific & Industrial Research Nitrofurfuryl substituted phenyl linked piperidino-oxadiazoline conjugates as anti-tubercular agents and process for the preparation thereof
WO2013139717A1 (en) 2012-03-19 2013-09-26 Smardtv S.A. A cicam system for processing multiple programme transport streams

Also Published As

Publication number Publication date
DK3030561T3 (en) 2017-03-27
PL3030561T3 (pl) 2017-08-31
PT3030561T (pt) 2017-03-23
KR20160030580A (ko) 2016-03-18
HRP20170277T1 (hr) 2017-05-19
ES2618072T3 (es) 2017-06-20
KR101665301B1 (ko) 2016-10-11
TW201518290A (zh) 2015-05-16
JP2016525071A (ja) 2016-08-22
EP3030561A1 (en) 2016-06-15
IN2013MU02611A (hu) 2015-06-12
CN105612154A (zh) 2016-05-25
TWI562990B (en) 2016-12-21
AR097282A1 (es) 2016-03-02
WO2015019365A1 (en) 2015-02-12
HK1222386A1 (zh) 2017-06-30
EP3030561B1 (en) 2017-01-11
WO2015019365A8 (en) 2016-02-18
US9556148B2 (en) 2017-01-31
US20160176849A1 (en) 2016-06-23

Similar Documents

Publication Publication Date Title
AU2018200277B2 (en) Compounds
DK2545045T3 (en) PIPERIDINE-4-YL-azetidine derivatives AS JAK1 INHIBITORS
US9073892B2 (en) Indazolyl triazol derivatives
JP5559362B2 (ja) ピペリジン誘導体
RU2679609C1 (ru) Производные имидазопиридазина в качестве модуляторов активности tnf
AU2018331456A1 (en) Pyrazolopyrimidinone compounds and uses thereof
AU2011328237A1 (en) Pyridine compounds and aza analogues thereof as TYK2 inhibitors
CA3056724A1 (en) Compounds useful in the treatment or prevention of a prmt5-mediated disorder
CA2950211C (en) 3-((piperazin-1-yl)methyl)-phenyl amide derivatives and their use as retinoid-related orphan receptor gamma (ror.gamma.) modulators
EA022075B1 (ru) Азотсодержащие гетероарильные соединения
EA020777B1 (ru) 4-пиразолил-n-арилпиримидин-2-амины, 4-пиразолил-n-пиразолилпиримидин-2-амины и 4-пиразолил-n-пиридилпиримидин-2-амины в качестве ингибиторов киназ janus
CA2875990A1 (en) Heterocyclyl pyrimidine analogues as tyk2 inhibitors
AU2013275209A1 (en) Branched chain alkyl heteroaromatic ring derivative
JP6529998B2 (ja) うつ病、糖尿病及びパーキンソン病のような幾つかの障害の処置において使用するためのｔａａｒ調節薬としてのピラゾールカルボキサミド誘導体
MXPA05004305A (es) Compuestos de triazol para el tratamiento de dismenorrea.
AU2013325615A1 (en) Imidazole derivative
RU2690154C2 (ru) Производные морфолин-пиридина
JP2007517007A (ja) Ｔｉｅ２（ＴＥＫ）活性を持つピリミジン
CA3001649C (en) Dopamine d3 receptor antagonists having a morpholine moiety
HUE033448T2 (hu) Janus kináz inhibitor N-cianometilamidok
KR20170029634A (ko) 중추신경계 장애의 치료를 위한 치환된 피라지노[2,1-a]이소퀴놀린 유도체